190 related articles for article (PubMed ID: 28765084)
1. Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.
Watson M; Soman A; Flagg EW; Unger E; Deapen D; Chen VW; Peres LC; Copeland G; Tucker TC; Garnett E; Saraiya M
Prev Med; 2017 Oct; 103():60-65. PubMed ID: 28765084
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
4. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
[TBL] [Abstract][Full Text] [Related]
5. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
Anttila A; Kotaniemi-Talonen L; Leinonen M; Hakama M; Laurila P; Tarkkanen J; Malila N; Nieminen P
BMJ; 2010 Apr; 340():c1804. PubMed ID: 20423964
[TBL] [Abstract][Full Text] [Related]
6. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
7. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of HPV associated cervical intraepithelial neoplasia in women under age 21: who will be missed under the new cervical cancer screening guidelines?
DeCew AE; Hadler JL; Daley AM; Niccolai L
J Pediatr Adolesc Gynecol; 2013 Dec; 26(6):346-9. PubMed ID: 24119656
[TBL] [Abstract][Full Text] [Related]
9. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of human papillomavirus (HPV)-vaccine types by race/ethnicity and sociodemographic factors in women with high-grade cervical intraepithelial neoplasia (CIN2/3/AIS), Alameda County, California, United States.
Saadeh K; Park I; Gargano JW; Whitney E; Querec TD; Hurley L; Silverberg M
Vaccine; 2020 Jan; 38(1):39-45. PubMed ID: 31611099
[TBL] [Abstract][Full Text] [Related]
11. Population-based surveillance for cervical cancer precursors in three central cancer registries, United States 2009.
Flagg EW; Datta SD; Saraiya M; Unger ER; Peters E; Cole L; Chen VW; Tucker T; Byrne MJ; Copeland G; Silva W; Watson M; Weinstock H
Cancer Causes Control; 2014 May; 25(5):571-81. PubMed ID: 24578200
[TBL] [Abstract][Full Text] [Related]
12. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.
Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S78-84. PubMed ID: 23519309
[TBL] [Abstract][Full Text] [Related]
13. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap.
Cameron RL; Kavanagh K; Cameron Watt D; Robertson C; Cuschieri K; Ahmed S; Pollock KG
J Epidemiol Community Health; 2017 Oct; 71(10):954-960. PubMed ID: 28756395
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial.
Rijkaart DC; Berkhof J; Rozendaal L; van Kemenade FJ; Bulkmans NW; Heideman DA; Kenter GG; Cuzick J; Snijders PJ; Meijer CJ
Lancet Oncol; 2012 Jan; 13(1):78-88. PubMed ID: 22177579
[TBL] [Abstract][Full Text] [Related]
15. Cytology and human papillomavirus screening test results associated with 2827 histopathologic diagnoses of cervical intraepithelial neoplasia 2/3.
Zhao C; Amin M; Weng B; Chen X; Kanbour-Shakir A; Austin RM
Arch Pathol Lab Med; 2013 Jul; 137(7):942-7. PubMed ID: 23050808
[TBL] [Abstract][Full Text] [Related]
16. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
17. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016.
Orumaa M; Leinonen MK; Campbell S; Møller B; Myklebust TÅ; Nygård M
Int J Cancer; 2019 Nov; 145(10):2629-2638. PubMed ID: 30734284
[TBL] [Abstract][Full Text] [Related]
18. [Investigation on the prevalence of high risk human papillomavirus and cervical cancer among adult women, in Shenzhen].
DU H; Wu RF; Tang HR; Wu LN; Zhang LJ; Liu ZH; Li J; Li RZ; Wang GP; Zhou YQ; Wang C; Weng LM
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):799-802. PubMed ID: 22967332
[TBL] [Abstract][Full Text] [Related]
19. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical intraepithelial neoplasia across 5 countries in Asia.
Quek SC; Lim BK; Domingo E; Soon R; Park JS; Vu TN; Tay EH; Le QT; Kim YT; Vu BQ; Cao NT; Limson G; Pham VT; Molijn A; Ramakrishnan G; Chen J
Int J Gynecol Cancer; 2013 Jan; 23(1):148-56. PubMed ID: 23221730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
